Prospective Comparison of Dual Wavelength Long-Pulsed 755-nm Alexandrite/1,064-nm Neodymium:Yttrium-Aluminum-Garnet Laser versus 585-nm Pulsed Dye Laser Treatment for Rosacea
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: Rosacea treatments including oral/topical medications and laser therapy are numerous but unsatisfactory. Objective: To compare the effectiveness of the dual wavelength long-pulsed 755-nm alexandrite/1,064-nm neodymium: yttrium-aluminum-garnet laser (LPAN) with that of 585-nm pulsed dye laser (PDL) for rosacea. Methods: This was a randomized, single-blinded, comparative study. Full face received four consecutive monthly treatments with LPAN or PDL, followed-up for 6 months after the last treatment. Erythema index was measured by spectrophotometer, and digital photographs were evaluated by consultant dermatologists for physician’s global assessment. Subjective satisfaction surveys and adverse effects were recorded. Results: Forty-nine subjects with rosacea enrolled and 12 dropped out. There were no significant differences between LPAN and PDL in the mean reduction of the erythema index (p=0.812; 3.6% vs. 2.8%), improvement of physician’s global assessment (p=1.000; 88.9% vs. 89.5%), and subject-rated treatment satisfaction (p=0.842; 77.8% vs. 84.2%). PDL showed more adverse effects including vesicles than LPAN (p=0.046; 26.3% vs. 0.0%). No other serious or permanent adverse events were observed in both treatments. Conclusion: Both LPAN and PDL may be effective and safe treatments for rosacea.
Abstract
Background: Rosacea treatments including oral/topical medications and laser therapy are numerous but unsatisfactory. Objective: To compare the effectiveness of the dual wavelength long-pulsed 755-nm alexandrite/1,064-nm neodymium: yttrium-aluminum-garnet laser (LPAN) with that of 585-nm pulsed dye laser (PDL) for rosacea. Methods: This was a randomized, single-blinded, comparative study. Full face received four consecutive monthly treatments with LPAN or PDL, followed-up for 6 months after the last treatment. Erythema index was measured by spectrophotometer, and digital photographs were evaluated by consultant dermatologists for physician’s global assessment. Subjective satisfaction surveys and adverse effects were recorded. Results: Forty-nine subjects with rosacea enrolled and 12 dropped out. There were no significant differences between LPAN and PDL in the mean reduction of the erythema index (p=0.812; 3.6% vs. 2.8%), improvement of physician’s global assessment (p=1.000; 88.9% vs. 89.5%), and subject-rated treatment satisfaction (p=0.842; 77.8% vs. 84.2%). PDL showed more adverse effects including vesicles than LPAN (p=0.046; 26.3% vs. 0.0%). No other serious or permanent adverse events were observed in both treatments. Conclusion: Both LPAN and PDL may be effective and safe treatments for rosacea.
참고문헌 (24)
- Erceg A., "The efficacy of pulsed dye laser treatment for inflammatory skin diseases : a systematic review", J Am Acad Dermatol, 69, pp.609~615 (2013)
- Powell FC., "Clinical practice. Rosacea", N Engl J Med, 352, pp.793~803 (2005)
- Crawford GH., "Rosacea: I. Etiology, pathogenesis, and subtype classification", J Am Acad Dermatol, 51, pp.327~341 (2004)
- Aksoy B., "The impact of rosacea on quality of life : effects of demographic and clinical characteristics and various treatment modalities", Br J Dermatol, 163, pp.719~725 (2010)
- Jansen T., "Clinical presentations and classification of rosacea", Ann Dermatol Venereol, 138(Suppl 3), pp.S192~S200 (2011)
- Yamasaki K., "The molecular pathology of rosacea", J Dermatol Sci, 55, pp.77~81 (2009)
- Reinholz M., "Rosacea-S1 guideline", J Dtsch Dermatol Ges, 11, pp.768~780 (2013)
- Cribier B, "Pathophysiology of rosacea: redness, telangiectasia, and rosacea", Ann Dermatol Venereol, 138(Suppl 3), pp.S184~S191 (2011)
- Schwab VD., "Neurovascular and neuroimmune aspects in the pathophysiology of rosacea", J Investig Dermatol Symp Proc, 15, pp.53~62 (2011)
- van Zuuren EJ., "Effective and evidence-based management strategies for rosacea : summary of a Cochrane systematic review", Br J Dermatol, 165, pp.760~781 (2011)
- Pelle MT., "Rosacea: II. Therapy", J Am Acad Dermatol, 51, pp.499~512 (2004)
- Elewski BE., "Rosacea-global diversity and optimized outcome : proposed international consensus from the Rosacea International Expert Group", J Eur Acad Dermatol Venereol, 25, pp.188~200 (2011)
- Baldwin HE., "Systemic therapy for rosacea", Skin Ther Lett, 12, pp.1-5~9 (2007)
- Richards KA., "The pulsed dye laser for cutaneous vascular and nonvascular lesions", Semin Cutan Med Surg, 19, pp.276~286 (2000)
- Alam M., "Comparative effectiveness of nonpurpuragenic 595-nm pulsed dye laser and microsecond 1064-nm neodymium : yttrium-aluminum-garnet laser for treatment of diffuse facial erythema : a double-blind randomized controlled trial", J Am Acad Dermatol, 69, pp.438~443 (2013)
- Jasim ZF., "Long-pulsed(6-ms)pulsed dye laser treatment of rosacea-associated telangiectasia using subpurpuric clinical threshold", Dermatol Surg, 30, pp.37~40 (2004)
- Zide BM., "Hemangioma update : pearls from 30 years of treatment", Ann Plast Surg, 69, pp.99~103 (2012)
- Kauvar AN., "Pulsed alexandrite laser for the treatment of leg telangiectasia and reticular veins", Arch Dermatol, 136, pp.1371~1375 (2000)
- Li L., "Comparison study of a long-pulse pulsed dye laser and a long-pulse pulsed alexandrite laser in the treatment of port wine stains", J Cosmet Laser Ther, 10, pp.12~15 (2008)
- Su W., "Beneficial effects of early treatment of infantile hemangiomas with a long-pulse Alexandrite laser", Lasers Surg Med, 46, pp.173~179 (2014)
- Ahcan U., "Port wine stain treatment with a dual-wavelength Nd : Yag laser and cryogen spray cooling : a pilot study", Lasers Surg Med, 34, pp.164~167 (2004)
- Schulz KF, "CONSORT 2010 Statement: updated guidelines for reporting parallel group randomized trials", Open Med, 4, pp.e60~e68 (2010)
- Say EM., "Treatment outcomes of long-pulsed Nd : YAG laser for two different subtypes of rosacea", J Clin Aesthet Dermatol, 8, pp.16~20 (2015)
- Tardío JC., "Pleomorphic dermal sarcoma : a more aggressive neoplasm than previously estimated", J Cutan Pathol, 43, pp.101~112 (2016)